HOME >> BIOLOGY >> NEWS
Vion Demonstrates Readiness Of First Tumor-Targeting Salmonella For Human Testing Against Solid Tumors

to manufacture and pharmacological formulation, and we have successfully produced sufficient quantities for initial clinical trials."

Vion scientists Caroline Clairmont, Ph.D. and Li-mou Zheng, Ph.D. also reported new preclinical data showing the safety of VNP20009 in non-human primate models. Previous studies in mice have demonstrated that VNP20009 is more than 10,000 times less toxic than the wild-type Salmonella strain from which it is developed. Additionally, the studies showed that the TAPET bacteria were rapidly cleared from the blood to undetectable levels within 24 hours. New research reported at AACR showed that VNP20009 has no toxic effect when administered to cynomolgous monkeys at very high doses (109 cfu/monkey), which would be toxic using wild-type Salmonella. Moreover, the bacterium is not shed in the animals' feces or urine, and is rapidly cleared from the blood and from other tissues over extended periods of time.

A further report at AACR by Vion scientists showed VNP20009's ability to inhibit the growth of both primary tumors and metastases. VNP20009, injected intravenously into tumor-bearing mice, accumulated and proliferated within tumor tissue at a rate at least 500 times higher than it did in liver, the tissue of second greatest accumulation. This selectivity for tumors was observed in a variety of tumor types, including mouse melanoma, and human melanoma, colon, lung, prostate, and breast tumors transplanted into mice. In addition, the researchers demonstrated that VNP20009 inhibited the growth of lung metastases in models of metastatic melanoma and prolonged the life span of animals treated with the TAPET organisms.

"These new findings further support Vion's position that TAPET organisms should be safe for use in humans and offer considerable potential as a new approach to the treatment of cancer," said Dr. Ivan King, vice president of biology. "Our research has shown TAPET to have a wide ranging ability t
'"/>

Contact: Joan Kureczka
jkureczka@aol.com
415-821-2413
Kureczka/Martin Associates
11-Apr-1999


Page: 1 2 3

Related biology news :

1. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
2. Engineering Animation, Inc. Demonstrates Internet Anatomy At Visible Human Project Conference
3. Study Demonstrates High Conservation Potential Of Logged Rainforest
4. First glimpse of DNA binding to viral enzyme
5. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults
6. 2nd media alert First Scientific Conference on Childhood Leukaemia
7. First International Scientific Conference on Childhood Leukaemia
8. First ever standards linking climate change, biodiversity and poverty seek global peer review
9. First genetic comparison of purebred domestic dogs produces surprises
10. First time in the U.S.: Saint Louis University tests third-generation vaccine against smallpox
11. First target for childhood malaria vaccine

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/4/2019)... ... December 04, 2019 , ... NDA Partners Chairman ... a regulatory toxicology expert with more than 20 years of experience working in ... Dr. Todd has extensive experience with a variety of biologic modalities including monoclonal ...
(Date:12/2/2019)... ... 01, 2019 , ... Each year The Scientist ... the life-science landscape. For more than a decade, our expert panels of independent ... biological discovery. This year’s crop of entries to The Scientist’s Top 10 Innovations ...
(Date:11/27/2019)... ... November 26, 2019 , ... ... their Glen Ellyn, IL practice for Invisalign® treatment. Invisalign orthodontics uses ... Patients with a misaligned bite, also known as malocclusion, present both functional and ...
Breaking Biology News(10 mins):
(Date:12/30/2019)... TOWNSHIP, N.J. (PRWEB) , ... December 30, 2019 ... ... of custom built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, Medical Device ... SIMS Version 1.11.19 21 CFR Part 11 compliant software program specific to the ...
(Date:12/27/2019)... , ... December 27, 2019 , ... ... studies for its 505(b)(2) product pipeline that offers patients and healthcare ... The products concepts were identified in collaboration with doctors and managed care professionals ...
(Date:12/18/2019)... SCOTTSDALE, Ariz. (PRWEB) , ... December 17, 2019 ... ... it has received its 31st FDA clearance for reprocessing Electrophysiology (EP) devices since ... where closest competitors, Stryker Sustainability Solutions and SterilMed (a Johnson & Johnson company) ...
(Date:12/18/2019)... ... December 18, 2019 , ... Tune in to CNBC ... by Ted Danson. Check local listings for more information on this program. , With ... reality are helping to simplify complex system to increase the efficiency, safety and effectiveness ...
Breaking Biology Technology:
Cached News: